Recent FDA-approved Therapeutics

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This Genetic Technology TOE profiles therapeutics that have been recently approved by FDA. The corresponding clinical trials scenario is also depicted along with industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks

Table of Contents

Recent FDA-approved TherapeuticsInnovation ProfilesFirst FDA Approved Immunotherapy for Metastatic Merkel Cell CarcinomaRelapsing Multiple Sclerosis Now Has a Novel FDA-approved Drug for TreatmentFDA-approved Therapy for Atopic DermatitisSuitable and Effective Therapeutic Approved for Recurrent Epithelial Ovarian Cancer Ovarian Cancer Clinical Trials Industry Contacts

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.